MDXH

MDXHEALTH SA

About MDXH

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

Buy US stocks in Australia starting with MDXH. Open an account and start investing today!

Market Capitalisation

$47.89M

Price-earnings ratio

Dividend yield

0.00%

Volume

47.27K

High today

$2.93

Low today

$2.79

Open price

$2.87

52-week high

$10.95

52-week low

$2.47

MDXH FAQs

How much is one share of MDXHEALTH SA?

One share of MDXHEALTH SA is valued at $2.82.

What is the ticker symbol for MDXHEALTH SA?

The ticker symbol for MDXHEALTH SA is MDXH.

How do I buy MDXH shares in Australia?

To buy MDXH stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake Wall St
Deposit directly into your Stake wallet and you're ready to invest in MDXH

What is the 52-week high for MDXHEALTH SA stock?

The MDXHEALTH SA 52-week high stock price is $10.95.

What is the 52-week low for MDXHEALTH SA stock?

The MDXHEALTH SA 52-week low stock price is $2.47.

What is the market capitalisation of MDXHEALTH SA MDXH?

As of 25/03/2023 MDXHEALTH SA has a market cap of $48M.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.